Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

Trial Profile

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PEACE III
  • Most Recent Events

    • 04 Jun 2019 The trial was amended (v4.0, April 19, 2018) to mandate that all patients must start a bone protecting agents (BPA), according to the results at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2019 Results (n=146, as of 28 Jan 2019) assessing fracture rate after mandatory continuous administration of bone protecting agents presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Sep 2018 Trial status has been changed from suspended to recruiting in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top